Abstract
Accumulating research supports the neuroprotective effects of pomegranate (Punica granatum) juice and extracts against Alzheimer’s disease (AD) but there is limited data available in animal models. Here we investigated the effects of a standardized pomegranate extract (PE) on AD pathology in an aged transgenic AD animal model (R1.40).The mice (age 24-30 months) received either PE (at 100 and 200 mg/kg) or a control solution daily for three weeks, and were evaluated in the Morris water maze and the Y-maze for improvements in spatial long-term and working memory functions. Cortical amyloid-β precursor protein (APP) and amyloid-β (Aβ) levels, along with other relevant biomarkers for AD, were measured in brain tissues. PE did not improve cognitive performance of the mice, but altered levels and ratio of the Aβ42 and Aβ40 peptides which would favor a diminution in AD pathogenesis. Further analysis revealed that this reversal could be the product of the modification of γ-secretase enzyme activity, the enzyme involved in the generation of these Aβ isoforms. Our findings support a specific anti-amyloidogenic mechanism of a pomegranate extract in this aged AD animal model.
Keywords: Alzheimer's disease, amyloid-β protein, gamma secretase, polyphenols, pomegranate.
Current Alzheimer Research
Title:Pomegranate Extract Modulates Processing of Amyloid-β Precursor Protein in an Aged Alzheimer`s Disease Animal Model
Volume: 11 Issue: 9
Author(s): Aseef H. Ahmed, Gehad M. Subaiea, Aseel Eid, Liya Li, Navindra P. Seeram and Nasser H. Zawia
Affiliation:
Keywords: Alzheimer's disease, amyloid-β protein, gamma secretase, polyphenols, pomegranate.
Abstract: Accumulating research supports the neuroprotective effects of pomegranate (Punica granatum) juice and extracts against Alzheimer’s disease (AD) but there is limited data available in animal models. Here we investigated the effects of a standardized pomegranate extract (PE) on AD pathology in an aged transgenic AD animal model (R1.40).The mice (age 24-30 months) received either PE (at 100 and 200 mg/kg) or a control solution daily for three weeks, and were evaluated in the Morris water maze and the Y-maze for improvements in spatial long-term and working memory functions. Cortical amyloid-β precursor protein (APP) and amyloid-β (Aβ) levels, along with other relevant biomarkers for AD, were measured in brain tissues. PE did not improve cognitive performance of the mice, but altered levels and ratio of the Aβ42 and Aβ40 peptides which would favor a diminution in AD pathogenesis. Further analysis revealed that this reversal could be the product of the modification of γ-secretase enzyme activity, the enzyme involved in the generation of these Aβ isoforms. Our findings support a specific anti-amyloidogenic mechanism of a pomegranate extract in this aged AD animal model.
Export Options
About this article
Cite this article as:
Ahmed H. Aseef, Subaiea M. Gehad, Eid Aseel, Li Liya, Seeram P. Navindra and Zawia H. Nasser, Pomegranate Extract Modulates Processing of Amyloid-β Precursor Protein in an Aged Alzheimer`s Disease Animal Model, Current Alzheimer Research 2014; 11 (9) . https://dx.doi.org/10.2174/1567205011666141001115348
DOI https://dx.doi.org/10.2174/1567205011666141001115348 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Drugs as Possible Triggers of Takotsubo Cardiomyopathy: A Comprehensive Literature Search - Update 2015
Current Clinical Pharmacology Diallyl Sulfide: Potential Use in Novel Therapeutic Interventions in Alcohol, Drugs, and Disease Mediated Cellular Toxicity by Targeting Cytochrome P450 2E1
Current Drug Metabolism Radiolabeled Sugars Used for PET and SPECT Imaging
Current Radiopharmaceuticals A Possible Link of Gut Microbiota Alteration in Type 2 Diabetes and Alzheimer’s Disease Pathogenicity: An Update
CNS & Neurological Disorders - Drug Targets Natural Compounds Used as Therapies Targeting to Amyotrophic Lateral Sclerosis
Current Pharmaceutical Biotechnology Kawasaki Disease and Its Treatment – An Update
Current Rheumatology Reviews The Neuroprotective Role of Repetitive Transcranial Magnetic Stimulation (rTMS) for Neurodegenerative Diseases: A Short Review on Experimental Studies
Mini-Reviews in Medicinal Chemistry Medicinal Chemistry of the Epigenetic Diet and Caloric Restriction
Current Medicinal Chemistry Anti-Copper Therapies in Alzheimers Disease: New Concepts
Recent Patents on CNS Drug Discovery (Discontinued) Editorial: Cocaine and Cerebral Small Vessel: Is it a Negative Factor for Intravenous Thrombolysis?
Current Vascular Pharmacology Fish Oil has Beneficial Effects on Behavior Impairment and Oxidative Stress in Rats Subjected to a Hepatic Encephalopathy Model
CNS & Neurological Disorders - Drug Targets A Review of Chemical Agents in the Pharmacotherapy of Addiction
Current Medicinal Chemistry Disruption of Circadian Rhythms and Delirium, Sleep Impairment and Sepsis in Critically ill Patients. Potential Therapeutic Implications for Increased Light-Dark Contrast and Melatonin Therapy in an ICU Environment
Current Pharmaceutical Design Evidence of Redox Unbalance in Post-Acute Ischemic Stroke Patients
Current Neurovascular Research A Comprehensive Analysis of Unique and Recurrent Copy Number Variations in Alzheimer’s Disease and its Related Disorders
Current Alzheimer Research The Association of ACT -17 A/T Polymorphism with Alzheimer’s Disease: A Meta-Analysis
Current Alzheimer Research CoMFA, CoMSIA and HQSAR Studies of Acetylcholinesterase Inhibitors
Current Computer-Aided Drug Design Benefits of Caloric Restriction on Brain Aging and Related Pathological States: Understanding Mechanisms to Devise Novel Therapies
Current Medicinal Chemistry Clinical Molecular Imaging with PET Agents Other than 18F-FDG
Current Pharmaceutical Biotechnology Sialic Acid and the Central Nervous System: Perspectives on Biological Functions, Detection, Imaging Methods and Manipulation
CNS & Neurological Disorders - Drug Targets